Announcements Trials
Browse Landscape

Status

Recruiting 301Completed 286Terminated 146Active not recruiting 136Unknown 122Not yet recruiting 84Withdrawn 50Suspended 10No longer available 4Enrolling by invitation 4Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Breast 4

Conditions

Multiple Myeloma 20Melanoma 16Prostatic Neoplasms 15Neoplasms 15Recurrence 13Carcinoma, Non-Small-Cell Lung 13Leukemia, Myeloid, Acute 12Glioblastoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Breast Neoplasms 7Sarcoma 6Neuroblastoma 6Lung Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Glioma 6Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Lambert-Eaton Myasthenic Syndrome 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neuroendocrine Tumors 4Liver Neoplasms 4Hodgkin Disease 4Carcinoma, Renal Cell 4Precancerous Conditions 3Pheochromocytoma 3

Interventions

veliparib 2leronlimab 1iniparib 1Vinorelbine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × Triple Negative Breast Neoplasms × Clear all
NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.

No longer available
Breast

Triple Negative Breast Neoplasms

NCT03123211 2022-05-24

Expanded Access to Veliparib

AbbVie

No longer available
Breast

Triple Negative Breast Neoplasms

NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

University of Washington

No longer available
Breast

Triple Negative Breast Neoplasms

NCT01130259 2013-09-17

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Sanofi

No longer available
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡